Filter by: patients
Home > Community Treatment Reports and Side Effects > Piracetam Treatment Report
What is Piracetam?

Piracetam is an antipsychotic agent used to enhance cognition in the elderly; for cortical myoclonus (seizures); and in sickle cell anemia. This product is available in various countries but not currently available in the U.S.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 3 2 Efficacy_slight Efficacy_cant_tell
General health 3 2 Efficacy_slight Efficacy_cant_tell
Brain fog 2 0
Support brain health 1 1 Efficacy_none
Dyslexia 1 0

See all 5 patients currently taking Piracetam

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 4

Reported Dosages

  1,600mg as needed 1 g daily 1,600 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Piracetam (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 2   Did not seem to work: 40%
Other 2   Other: 40%
Expense 1   Expense: 20%
Personal research 1   Personal research: 20%

See all 5 patients who’ve stopped taking Piracetam

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Piracetam

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Piracetam

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Piracetam

Always
 1 25%
Usually
 1 25%
Sometimes
 1 25%
Never
 1 25%

Burden

Difficulty being on treatment

Burden of Piracetam

Very
 0 0%
Somewhat
 0 0%
A little
 1 25%
Not at all
 3 75%

Cost

Paid out of pocket

Cost of Piracetam

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on February 09, 2012.